Daniel J Vis
Overview
Explore the profile of Daniel J Vis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
2604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vis D, Jaaks P, Aben N, Coker E, Barthorpe S, Beck A, et al.
Cell Rep Med
. 2024 Aug;
5(8):101687.
PMID: 39168097
Combining drugs can enhance their clinical efficacy, but the number of possible combinations and inter-tumor heterogeneity make identifying effective combinations challenging, while existing approaches often overlook clinically relevant activity. We...
2.
Chelushkin M, van Dorp J, van Wilpe S, Seignette I, Mellema J, Alkemade M, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4227-4239.
PMID: 39047168
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as...
3.
Gil-Jimenez A, van Dijk N, Vos J, Lubeck Y, van Montfoort M, Peters D, et al.
Nat Commun
. 2024 Mar;
15(1):2538.
PMID: 38514623
Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between the TME, usually characterized by immune...
4.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis D, Braaf L, et al.
Eur Urol
. 2023 Mar;
83(6):e165.
PMID: 36907692
No abstract available.
5.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis D, Braaf L, et al.
Eur Urol
. 2022 Aug;
83(4):313-317.
PMID: 35965206
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that somatic deleterious mutations in ERCC2, gain-of-function mutations in...
6.
Jaaks P, Coker E, Vis D, Edwards O, Carpenter E, Leto S, et al.
Nature
. 2022 Feb;
603(7899):166-173.
PMID: 35197630
Combinations of anti-cancer drugs can overcome resistance and provide new treatments. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations...
7.
van Dijk N, Gil-Jimenez A, Silina K, van Montfoort M, Einerhand S, Jonkman L, et al.
Front Immunol
. 2022 Jan;
12:793964.
PMID: 34987518
Candidate immune biomarkers have been proposed for predicting response to immunotherapy in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. A comprehensive overview of the tumor...
8.
Mourragui S, Loog M, Vis D, Moore K, Manjon A, van de Wiel M, et al.
Proc Natl Acad Sci U S A
. 2021 Dec;
118(49).
PMID: 34873056
Preclinical models have been the workhorse of cancer research, producing massive amounts of drug response data. Unfortunately, translating response biomarkers derived from these datasets to human tumors has proven to...
9.
Schouten P, Richters L, Vis D, Kommoss S, van Dijk E, Ernst C, et al.
Clin Cancer Res
. 2021 Oct;
27(23):6559-6569.
PMID: 34593530
Purpose: Previously, we developed breast cancer like and -like copy-number profile shrunken centroid classifiers predictive for mutation status and response to therapy, targeting homologous recombination deficiency (HRD). Therefore, we investigated...
10.
van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit L, de Feijter J, et al.
Nat Med
. 2020 Oct;
26(12):1839-1844.
PMID: 33046870
Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown remarkable pathological responses in melanoma and colorectal cancer. In NABUCCO (ClinicalTrials.gov: NCT03387761 ), a single-arm feasibility trial, 24 patients with stage...